"N Engl J Med"[journal] 检索结果

161. U.S. Research Leadership at a Crossroads - The Impact of Reducing NIH Indirect-Cost Coverage.

作者: Amar H Kelkar.
来源: N Engl J Med. 2025年392卷21期2081-2084页

162. Judicial Invalidation of the FDA's Laboratory-Developed Test Rule - Legal and Public Health Consequences.

作者: Rachel E Sachs.;Joshua M Sharfstein.;Patricia J Zettler.
来源: N Engl J Med. 2025年392卷20期e49页

163. More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.

作者: Yoshitomo Hoshino.;Kazuo Okamoto.;Nobuaki Ito.
来源: N Engl J Med. 2025年392卷18期1871-1872页

164. More on Acquired Osteomalacia and Autoantibodies against PHEX.

作者: Salvatore Minisola.;Jessica Pepe.;Cristiana Cipriani.
来源: N Engl J Med. 2025年392卷18期1871页

165. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Reply.

作者: Marianna Fontana.;Ronald M Witteles.;Satish A Eraly.
来源: N Engl J Med. 2025年392卷18期1870-1871页

166. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

作者: Mohamad Zaidan.
来源: N Engl J Med. 2025年392卷18期1870页

167. Cabozantinib in Advanced Neuroendocrine Tumors. Reply.

作者: Jennifer A Chan.;Susan Geyer.;Jeffrey A Meyerhardt.
来源: N Engl J Med. 2025年392卷18期1869-1870页

168. Cabozantinib in Advanced Neuroendocrine Tumors.

作者: Diamantis I Tsilimigras.
来源: N Engl J Med. 2025年392卷18期1869页

169. Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.

作者: Claudia K Fox.;Nina M Harder-Lauridsen.;Silva Arslanian.
来源: N Engl J Med. 2025年392卷18期1868页

170. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Josephine M Egan.;Dimitrios Kapogiannis.
来源: N Engl J Med. 2025年392卷18期1866-1868页

171. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Conghua Ji.;Minyan Wang.
来源: N Engl J Med. 2025年392卷18期1867页

172. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Saul Malozowski.
来源: N Engl J Med. 2025年392卷18期1866-1867页

173. Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.

作者: Franziska Scheibe.;Julia Melchert.;Helena Radbruch.;Eberhard Siebert.;Till D Best.;Siegfried Kohler.;Mira Fitzek.;Alexander Kowski.;Volker Siffrin.;Jenny Meinhardt.;Raphael Raspe.;Viktor Horst.;Bianca Zukunft.;Klemens Budde.;Frank K H van Landeghem.;Christopher Power.;Kai-Uwe Eckardt.;Matthias Endres.;Christian Drosten.;Victor M Corman.;Klemens Ruprecht.
来源: N Engl J Med. 2025年392卷18期1864-1866页

174. Automated Insulin Pump in Type 2 Diabetes.

作者: Betul Hatipoglu.
来源: N Engl J Med. 2025年392卷18期1862-1863页

175. To BCG or Not Two BCG.

作者: Stephen M Carpenter.;W Henry Boom.
来源: N Engl J Med. 2025年392卷18期1860-1862页

176. Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma.

作者: Francesco Maura.;P Leif Bergsagel.
来源: N Engl J Med. 2025年392卷18期1858-1860页

177. Case 13-2025: A 70-Year-Old Man with Weight Loss, Weakness, and Anorexia.

作者: Matthew G Gartland.;Samuel C D Cartmell.;John S Albin.;Daniel Restrepo.;Anthony R Russo.
来源: N Engl J Med. 2025年392卷18期1847-1856页

178. Sea Anemone Sting.

作者: Weniko Caré.;Raphaële Mestiri.
来源: N Engl J Med. 2025年392卷18期e43页

179. Chemical Complexity of Food and Implications for Therapeutics.

作者: Giulia Menichetti.;Albert-László Barabási.;Joseph Loscalzo.
来源: N Engl J Med. 2025年392卷18期1836-1845页

180. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.

作者: Jakub Svoboda.;Daniel J Landsburg.;James Gerson.;Sunita D Nasta.;Stefan K Barta.;Elise A Chong.;Michael Cook.;Noelle V Frey.;Joanne Shea.;Amanda Cervini.;Amy Marshall.;Megan Four.;Megan M Davis.;Julie K Jadlowsky.;Anne Chew.;Edward Pequignot.;Vanessa Gonzalez.;Julia Han Noll.;Luca Paruzzo.;Juliana Rojas-Levine.;Gabriela Plesa.;John Scholler.;Donald L Siegel.;Bruce L Levine.;David L Porter.;Saba Ghassemi.;Marco Ruella.;Andrew Rech.;Rachel M Leskowitz.;Joseph A Fraietta.;Wei-Ting Hwang.;Elizabeth Hexner.;Stephen J Schuster.;Carl H June.
来源: N Engl J Med. 2025年392卷18期1824-1835页

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity.

结果排序

文献格式

出版时间

出版类型

出版语言